Transfusion‐transmitted CMV infection – current knowledge and future perspectives

Transfusion Medicine - Tập 27 Số 4 - Trang 238-248 - 2017
Malte Ziemann1, Thomas Thiele2
1Institut für Transfusionsmedizin Universitätsklinikum Schleswig Holstein Lübeck Germany
2Institut für Immunologie und Transfusionsmedizin, Abteilung Transfusionsmedizin Universitätsmedizin Greifswald Greifswald Germany

Tóm tắt

SUMMARY

Transmission of human cytomegalovirus (CMV) via transfusion (TT‐CMV) may still occur and remains a challenge in the treatment of immunocompromised CMV‐seronegative patients, e.g. after stem cell transplantation, and for low birthweight infants. Measures to reduce the risk of TT‐CMV have been evaluated in clinical studies, including leucocyte depletion of cellular blood products and/or the selection of CMV‐IgG‐negative donations. Studies in large blood donor cohorts indicate that donations from newly CMV‐IgG‐positive donors should bear the highest risk for transmitting CMV infections because they contain the highest levels of CMV‐DNA, and early CMV antibodies cannot neutralise CMV. Based on this knowledge, rational strategies to reduce the residual risk of TT‐CMV using leucoreduced blood products could be designed. However, there is a lack of evidence that CMV is still transmitted by transfusion of leucoreduced units. In low birthweight infants, most (if not all) CMV infections are caused by breast milk feeding or congenital transmission rather than by transfusion of leucoreduced blood products. For other patients at risk, no definitive data exist about the relative importance of alternative transmission routes of CMV compared to blood transfusion. As a result, only the conduction of well‐designed studies addressing strategies to prevent TT‐CMV and the thorough examination of presumed cases of TT‐CMV will achieve guidance for the best transfusion regimen in patients at risk.

Từ khóa


Tài liệu tham khảo

10.1111/trf.13503

10.3389/fmicb.2015.01016

10.1182/blood-2012-08-448977

10.1182/blood.V93.1.394

10.1182/blood.V86.9.3598.bloodjournal8693598

10.1001/jama.285.12.1592

10.1016/j.jviromet.2008.03.023

10.1111/trf.13605

10.1186/s41043-017-0079-z

10.1136/bmj.4.5684.660

10.1002/rmv.544

10.1111/j.1537-2995.2007.01494.x

10.1046/j.1537-2995.2003.00337.x

10.1182/blood.V97.11.3640

10.1111/trf.12390

10.1016/j.humimm.2004.02.009

10.1046/j.1537-2995.2003.00534.x

10.1053/j.semperi.2012.04.004

10.1111/tme.12219

10.1128/JCM.01495-15

10.1111/j.0042-9007.2004.00388.x

10.1093/clinids/12.Supplement_7.S701

10.1097/MD.0000000000001835

10.1001/jamapediatrics.2014.1360

10.1159/000381626

10.1136/bmj.1.5498.1270

10.1016/j.bbmt.2013.09.013

10.1097/TP.0b013e3181cee42f

10.4103/0377-4929.42509

10.1111/trf.13459

10.1046/j.1537-2995.1977.17477216868.x

10.1002/jmv.1890360110

10.1111/vox.12103

10.1309/PVFR-DDWE-302T-WFA1

10.1097/MOH.0000000000000085

10.1080/00365540110080412

10.1007/BF01497304

10.1111/trf.13478

10.1111/j.1537-2995.2006.00778.x

10.1111/j.1537-2995.2009.02334.x

10.1111/tme.12264

10.1111/trf.14001

10.1111/j.1537-2995.2012.03739.x

10.1046/j.1537-2995.1999.39299154736.x

10.1056/NEJMoa0804749

10.1371/journal.pone.0081881

10.1128/CVI.00487-14

10.1038/bmt.2010.35

10.1128/CMR.15.4.680-715.2002

10.1086/515277

10.1002/rmv.353

10.1046/j.1537-2995.2000.40050500.x

10.1046/j.1537-2995.2001.41101249.x

10.1046/j.1537-2995.2003.00312.x

10.1016/j.trre.2014.01.001

10.1159/000365646

10.1111/vox.12250

10.1016/S0092-8674(01)80014-3

10.1128/JVI.73.8.7027-7030.1999

10.1001/jama.1986.03380140074025

10.1093/infdis/142.1.102

10.1111/j.1537-2995.2011.03203.x

10.1016/j.trre.2016.04.001

10.1016/j.tmrv.2005.02.002

10.1182/blood-2003-03-0762

10.1128/JCM.01091-15

10.1111/j.1537-2995.2009.02486.x

10.1111/j.1442-200X.1995.tb03353.x

10.1086/314939

10.1111/j.1537-2995.2007.01420.x

10.1111/j.1423-0410.2009.01306.x

10.1111/trf.12074

10.1111/trf.12199

Thông tin
Thông tin xuất bản

Transfusion Medicine

Tập 27 Số 4

238-248

Thông tin tác giả